Semaglutide treatment effects on liver fat content in obese subjects with Metabolic-Associated Steatotic Liver Disease (MASLD)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085178" target="_blank" >RIV/00023001:_____/24:00085178 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11310/24:10497205

Výsledek na webu

<a href="https://www.mdpi.com/2077-0383/13/20/6100" target="_blank" >https://www.mdpi.com/2077-0383/13/20/6100</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jcm13206100" target="_blank" >10.3390/jcm13206100</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Semaglutide treatment effects on liver fat content in obese subjects with Metabolic-Associated Steatotic Liver Disease (MASLD)

Popis výsledku v původním jazyce

Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) represents a major clinical complication of obesity. Methods: In this study, we used magnetic resonance (MR) methods to determine the effect of obesity treatment with semaglutide, a GLP-1 receptor agonist, on the liver fat content and selected metabolic variables. We investigated whether treatment would affect the acute response of liver fat to glucose and fructose administration and whether it would affect the fatty acid profile of VLDL-triglycerides. Sixteen obese non-diabetic men underwent a 16-week dietary intervention and 16-week treatment with subcutaneous semaglutide in a crossover design without a washout period. The order of the interventions was randomized. Results: After treatment, body weight of the subjects decreased by 5% and liver fat by a third, whereas dietary intervention had no impact on these parameters. The decrease in liver fat with semaglutide did not correlate with changes in body weight and other measures of adiposity and was unrelated to improved insulin sensitivity. Conclusions: The proportion of palmitic and palmitoleic acids in VLDL-triglycerides decreased after treatment, suggesting that the beneficial effects of semaglutide on liver fat are mediated by the suppression of de novo lipogenesis.

Název v anglickém jazyce

Semaglutide treatment effects on liver fat content in obese subjects with Metabolic-Associated Steatotic Liver Disease (MASLD)

Popis výsledku anglicky

Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) represents a major clinical complication of obesity. Methods: In this study, we used magnetic resonance (MR) methods to determine the effect of obesity treatment with semaglutide, a GLP-1 receptor agonist, on the liver fat content and selected metabolic variables. We investigated whether treatment would affect the acute response of liver fat to glucose and fructose administration and whether it would affect the fatty acid profile of VLDL-triglycerides. Sixteen obese non-diabetic men underwent a 16-week dietary intervention and 16-week treatment with subcutaneous semaglutide in a crossover design without a washout period. The order of the interventions was randomized. Results: After treatment, body weight of the subjects decreased by 5% and liver fat by a third, whereas dietary intervention had no impact on these parameters. The decrease in liver fat with semaglutide did not correlate with changes in body weight and other measures of adiposity and was unrelated to improved insulin sensitivity. Conclusions: The proportion of palmitic and palmitoleic acids in VLDL-triglycerides decreased after treatment, suggesting that the beneficial effects of semaglutide on liver fat are mediated by the suppression of de novo lipogenesis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

<a href="/cs/project/NU20-01-00121" target="_blank" >NU20-01-00121: Vliv podávání semaglutidu na dynamiku akutní odpovědi obsahu tuku v játrech na zátěž jednoduchými sacharidy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of clinical medicine

ISSN

2077-0383

e-ISSN

2077-0383

Svazek periodika

13

Číslo periodika v rámci svazku

20

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

12

Strana od-do

"art. no. 6100"

Kód UT WoS článku

001341403100001

EID výsledku v databázi Scopus

2-s2.0-85207670737